SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-265591
Filing Date
2024-11-26
Accepted
2024-11-26 06:49:33
Documents
17
Period of Report
2024-11-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d881793d8k.htm   iXBRL 8-K 66179
2 EX-2.1 d881793dex21.htm EX-2.1 705147
3 EX-10.1 d881793dex101.htm EX-10.1 54049
4 EX-99.1 d881793dex991.htm EX-99.1 18460
8 GRAPHIC g881793dsp00194.jpg GRAPHIC 4556
  Complete submission text file 0001193125-24-265591.txt   1187450

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA pstx-20241125.xsd EX-101.SCH 2839
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20241125_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20241125_pre.xml EX-101.PRE 11700
19 EXTRACTED XBRL INSTANCE DOCUMENT d881793d8k_htm.xml XML 3777
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 241498119
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)